A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
Japan's Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ -- Prolacta Bioscience® today announced that Japan's Ministry of Health,...
Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan
Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain...
Improved Survival and Growth While Cutting Malnutrition for Premature Infants Fed Human Milk-Based Fortifiers at Sydney Hospital
Study Demonstrates Multiple Benefits of Prolacta's Exclusive Human Milk Diet Compared to Traditional Cow Milk-Based Feeding Protocol ADELAIDE, Australia, May 13, 2025 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provider of...
Adoption of an Exclusive Human Milk Diet Reduces Malnutrition Rates Among Vulnerable Premature Infants in Sydney Hospital
Preliminary Data From Observational Study Presented at Australian and New Zealand Neonatal Network Clinical Practice Improvement Conference ADELAIDE, Australia, Dec. 10, 2024 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital...